Amgen Inc (AMGN): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Amgen ( AMGN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole was unchanged today. By the end of trading, Amgen rose $2.18 (1.8%) to $122.29 on average volume. Throughout the day, 4,521,053 shares of Amgen exchanged hands as compared to its average daily volume of 3,391,000 shares. The stock ranged in a price between $120.50-$123.98 after having opened the day at $121.31 as compared to the previous trading day's close of $120.11. Other companies within the Drugs industry that increased today were: Northwest Biotherapeutics ( NWBO), up 15.1%, Genvec ( GNVC), up 13.7%, Inovio Pharmaceuticals ( INO), up 12.7% and MEI Pharma ( MEIP), up 12.1%.

Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Amgen has a market cap of $91.1 billion and is part of the health care sector. Shares are up 5.3% year to date as of the close of trading on Wednesday. Currently there are 7 analysts that rate Amgen a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.

On the negative front, Advaxis Incorporated ( ADXS), down 24.8%, Heat Biologics ( HTBX), down 9.8%, Egalet ( EGLT), down 9.4% and Endocyte ( ECYT), down 8.3% , were all laggards within the drugs industry with Allergan ( AGN) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

FDA Approves First 'Biosimilar' for Cancer Treatment

Amgen Builds on a Breakout

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback